Defendant Name:
ImmunoCellular Therapeutics, Ltd.
Defendant Type:
Public Company
SIC Code:
2834
CUSIP:
45253620
Document Reference:
33-10338
Document Details
Legal Case Name
In the Matter of ImmunoCellular Therapeutics, Ltd.
Document Name
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
Document Date
10-Apr-2017
Document Format
Administrative Proceeding
Allegation Type
Market Manipulation
Document Summary
On April 10, 2017, the SEC instituted a settled proceeding against ImmunoCellular Therapeutics, Ltd. According to the SEC: "[f]rom September 2011 to August 2012, IMUC through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors by commissioning over 50 internet publications promoting IMUC on investment websites that purported to be independent from the company when, in fact, they were paid promotions ... As a consequence of this conduct, IMUC violated the anti-fraud and caused violations of the anti-touting provisions of the federal securities laws.
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Other Compliance Related Undertaking
